A detailed history of Park Avenue Securities LLC transactions in Genmab A/S stock. As of the latest transaction made, Park Avenue Securities LLC holds 10,888 shares of GMAB stock, worth $224,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,888
Previous 13,790 21.04%
Holding current value
$224,183
Previous $347,000 23.63%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$23.84 - $28.48 $69,183 - $82,648
-2,902 Reduced 21.04%
10,888 $265,000
Q2 2024

Jul 09, 2024

SELL
$25.13 - $30.27 $11,584 - $13,954
-461 Reduced 3.23%
13,790 $347,000
Q1 2024

Apr 10, 2024

SELL
$26.43 - $32.77 $29,760 - $36,899
-1,126 Reduced 7.32%
14,251 $426,000
Q4 2023

Jan 10, 2024

SELL
$27.94 - $35.44 $32,214 - $40,862
-1,153 Reduced 6.98%
15,377 $490,000
Q3 2023

Oct 26, 2023

BUY
$35.27 - $42.24 $66,554 - $79,706
1,887 Added 12.89%
16,530 $583,000
Q2 2023

Jul 14, 2023

SELL
$37.4 - $42.94 $3,291 - $3,778
-88 Reduced 0.6%
14,643 $557,000
Q1 2023

Apr 18, 2023

BUY
$34.88 - $43.22 $49,076 - $60,810
1,407 Added 10.56%
14,731 $556,000
Q4 2022

Jan 24, 2023

SELL
$33.8 - $47.06 $202 - $282
-6 Reduced 0.05%
13,324 $0
Q3 2022

Nov 01, 2022

BUY
$31.52 - $373.61 $69,816 - $827,546
2,215 Added 19.93%
13,330 $428,000
Q2 2022

Jul 27, 2022

SELL
$26.83 - $38.57 $965 - $1,388
-36 Reduced 0.32%
11,115 $361,000
Q1 2022

Apr 29, 2022

BUY
$30.95 - $39.68 $866 - $1,111
28 Added 0.25%
11,151 $403,000
Q4 2021

Apr 08, 2022

BUY
$35.87 - $47.12 $717 - $942
20 Added 0.18%
11,123 $440,000
Q3 2021

Oct 21, 2021

BUY
$41.55 - $48.72 $13,337 - $15,639
321 Added 2.98%
11,103 $485,000
Q2 2021

Aug 05, 2021

BUY
$32.88 - $44.57 $60,038 - $81,384
1,826 Added 20.39%
10,782 $440,000
Q1 2021

Apr 28, 2021

BUY
$30.92 - $44.4 $34,877 - $50,083
1,128 Added 14.41%
8,956 $294,000
Q4 2020

Jan 20, 2021

BUY
$33.66 - $40.76 $263,490 - $319,069
7,828 New
7,828 $318,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Park Avenue Securities LLC Portfolio

Follow Park Avenue Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Park Avenue Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Park Avenue Securities LLC with notifications on news.